We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Lifemel Honey to Reduce Leucopenia During Chemotherapy

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2005 by Rambam Health Care Campus.
Recruitment status was:  Not yet recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00243165
First Posted: October 21, 2005
Last Update Posted: December 7, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Zuf Globus Laboratories Ltd.
Information provided by:
Rambam Health Care Campus
October 20, 2005
October 21, 2005
December 7, 2009
November 2005
Not Provided
Prevention of myelotoxicity-every week during chemotherapy.
Same as current
Complete list of historical versions of study NCT00243165 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Lifemel Honey to Reduce Leucopenia During Chemotherapy
Lifemel Honey During Adjuvant Chemotherapy for Breast Cancer Patients to Prevent Leucopenia
This study will include 60 patients with early breast cancer referred to receive adjuvant chemotherapy with AC ( adriamycin- cyclophosphamide) or CAF ( adriamycin- cyclophosphamide- 5- fluorouracil ) combinations. These patients will receive every day one spoon of Lifemel honey or regular honey ( double blind)- during the adjuvant chemotherapy .Every week a WBC count will be performed in order to record the influence of Lifemel on myelotoxicity.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Breast Cancer
Behavioral: Lifemel honey intake every day
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
60
Not Provided
Not Provided

Inclusion Criteria:

  • breast cancer patient treated with adjuvant chemotherapy
  • PS = 2 or less

Exclusion Criteria:

Sexes Eligible for Study: Female
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00243165
LifemelCTIL
Not Provided
Not Provided
Not Provided
Not Provided
Rambam Health Care Campus
Zuf Globus Laboratories Ltd.
Principal Investigator: Georgeta Fried, MD Rambam Health Care Campus
Rambam Health Care Campus
October 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP